These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31266741)

  • 1. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
    Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
    Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
    Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A
    Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
    Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
    J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
    Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
    Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
    Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
    Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
    J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
    Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
    Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
    Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
    [No Abstract]   [Full Text] [Related]  

  • 14. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.
    Bachanova V; Sarhan D; DeFor TE; Cooley S; Panoskaltsis-Mortari A; Blazar BR; Curtsinger JM; Burns L; Weisdorf DJ; Miller JS
    Cancer Immunol Immunother; 2018 Mar; 67(3):483-494. PubMed ID: 29218366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with double-bright (CD56
    Silla L; Valim V; Pezzi A; da Silva M; Wilke I; Nobrega J; Vargas A; Amorin B; Correa B; Zambonato B; Scherer F; Merzoni J; Sekine L; Huls H; Cooper LJ; Paz A; Lee DA
    Br J Haematol; 2021 Dec; 195(5):710-721. PubMed ID: 34490616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
    Boyiadzis M; Agha M; Redner RL; Sehgal A; Im A; Hou JZ; Farah R; Dorritie KA; Raptis A; Lim SH; Wang H; Lapteva N; Mei Z; Butterfield LH; Rooney CM; Whiteside TL
    Cytotherapy; 2017 Oct; 19(10):1225-1232. PubMed ID: 28864289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
    Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
    Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.
    Williams RL; Cooley S; Bachanova V; Blazar BR; Weisdorf DJ; Miller JS; Verneris MR
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):618-622. PubMed ID: 29197679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic applications: natural killer cells in the clinic.
    Miller JS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.
    Kottaridis PD; North J; Tsirogianni M; Marden C; Samuel ER; Jide-Banwo S; Grace S; Lowdell MW
    PLoS One; 2015; 10(6):e0123416. PubMed ID: 26062124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.